Device Trial Radar · NCT07923019
BRIGHT-LIGHT: Studying Red Light Therapy for Severe Short-Sightedness or Short-Sightedness That Worsens Despite Standard Treatment
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 31, 2030
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- Singapore National Eye CentreGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Singapore Eye Research Institute
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 8 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Some children's short-sightedness (myopia) continues to worsen despite treatments such as atropine eye drops, myopia-control spectacles or contact lenses. These children may be at greater risk of developing severe short-sightedness and related eye problems later in life. The BRIGHT-LIGHT study will assess the safety of repeated low-level red-light therapy and explore whether it can slow worsening short-sightedness in children whose myopia is inadequately controlled by conventional treatment. This therapy uses a device that delivers low-power red light to the eyes during short treatment sessions. Forty children aged 8-16 years will be followed for 12 months: 30 receiving red-light therapy and 10 continuing conventional myopia treatment. Group assignment will depend on the willingness of children and their parents or guardians to start red-light therapy, rather than random allocation. The main focus is safety, assessed through vision tests, detailed eye scans and tests of retinal function. The study will also assess changes in eye length and spectacle prescription to explore the treatment's effect on myopia progression.
Conditions
- Myopia
- Myopia Progressing
- Myopia Progression
- Light
Interventions
Repeated low-level red-light (RLRL) therapyDevice
Repeated low-level red-light (RLRL) therapy will be administered using the Eyerising Myopia Management Device, which delivers red light at a wavelength of 650 ± 10 nm and an output power of 2.0 ± 0.5 mW. Treatment consists of 3-minute sessions, twice per treatment day, separated by at least 4 hours, with a maximum of 10 sessions per week over 12 months. Participants may continue existing myopia-control spectacles or multifocal contact lenses alongside RLRL or switch to RLRL alone. Atropine eye drops must be discontinued before starting RLRL.
Continued existing myopia treatment strategyOther
Children are continued on existing myopia treatment strategy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Best-Corrected Visual AcuityTime frame: Baseline to 12 months, with assessments at 1, 3, 6 and 12 months.
- Occurrence of Retinal Structural AbnormalitiesTime frame: Throughout the 12-month study period.
- Occurrence of Retinal Functional AbnormalitiesTime frame: Throughout the 12-month study period.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Singapore Eye Research Institute
Singapore, Singapore
Singapore National Eye Centre
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.